AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
Phase 1
Completed
- Conditions
- Advanced Solid Malignancies
- Interventions
- Drug: MEDI9447 (oleclumab)
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT03736473
- Locations
- 🇯🇵
Research Site, Chuo-ku, Japan
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Phase 3
Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 895
- Registration Number
- NCT03732820
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
Phase 3
Active, not recruiting
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1063
- Registration Number
- NCT03732677
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients
Completed
- Conditions
- Non-small-cell Lung Cancer (NSCLC)
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3111
- Registration Number
- NCT03725475
- Locations
- 🇺🇾
Research Site, Montevideo, Uruguay
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 463
- Registration Number
- NCT03721289
- Locations
- 🇺🇾
Research Site, Montevideo, Uruguay
AZD4635 Relative Bioavailability Study
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AZD4635 solid oral formulation - fastedDrug: AZD4635 50 mg nano-suspension (reference)Drug: AZD4635 solid oral formulation - fedDrug: AZD4635 solid oral formulation variant 1 - fastedDrug: AZD4635 solid oral formulation variant 2 - fastedDrug: [14C] AZD4635 IV microtracer - fasted
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT03710434
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Phase 3
Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Other: Placebo
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 407
- Registration Number
- NCT03706690
- Locations
- 🇹🇷
Research Site, Malatya, Turkey
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: TezepelumabOther: Placebo
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 951
- Registration Number
- NCT03706079
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Phase 3
Active, not recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 730
- Registration Number
- NCT03703297
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10000
- Registration Number
- NCT03694470
- Locations
- 🇷🇺
Research site, Moscow, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath